Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

United Therapeutics, Supernus formulate UT15C

Executive Summary

Shire’s drug delivery technology division Supernus Pharmaceuticals and United Therapeutics (develops drugs for cancer and cardiovascular and infectious diseases) will develop UT's UT15C, an oral prostacyclin analog. Supernus has licensed UT rights to use its EnSoTrol osmotic technology to formulate UT15C tablets for twice-daily administration for pulmonary arterial hypertension (PAD) and potentially other indications.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Intra-Biotech Deal
    • R+D and Marketing-Licensing

Related Companies